stockrow
Saturday 7 November 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
- EPS
- −18.6%
- Free cash flow
- −64.8%
Quarter to September 2026, against a year earlier
24.48
0.76
+3.20%
Follow RAPP
Alert me
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Current Ratio |
18.80 | 17.14 | 35.34 | 26.17 |
Net Debt/EBITDA |
3.01 | 4.08 | 3.57 | 3.91 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.30 | 0.78 | 0.83 | 0.78 |
Capex/Depreciation |
(352.27) | (44.22) | 1.01 | 1.63 |
Interest Coverage |
(36.38) | — | — | — |
| 0.00% | 194.90% | (55.97%) | (28.22%) | |
| 0.00% | (37.20%) | (33.30%) | (26.95%) | |
ROIC |
0.00% | 0.00% | (123,593.75%) | 0.00% |
Return on Tangible Assets |
(35.58%) | (24.16%) | (25.71%) | (23.11%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(10.97) | (19.13) | (3.24) | (2.26) |
Cash per Share |
40.10 | 97.98 | 14.73 | 12.60 |
Shareholders Equity per Share |
25.10 | 93.59 | 14.73 | 12.45 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
25.10 | 93.59 | 14.73 | 12.45 |
Free Cash Flow |
(8.53) | (28.82) | (67.23) | (88.09) |
Working Capital |
29.61 | 142.07 | 301.04 | 479.51 |
Capital Expenditures |
(5.28) | (1.64) | (2.40) | (0.62) |
Net Current Asset Value |
19.17 | 136.39 | 300.30 | 470.78 |
| Other line items | ||||
Quick Ratio |
18.74 | 16.76 | 34.83 | 25.76 |
Depreciation/Fixed assets |
0.04 | 0.02 | (0.67) | (0.13) |
Cash ROIC |
(16.83%) | (9.99%) | (11.01%) | (9.03%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(4.17) | (18.05) | (3.13) | (2.25) |
Capex per Share |
(6.80) | (1.09) | (0.12) | (0.02) |
Average Payables |
— | 1.98 | 2.23 | 3.07 |
Average Assets |
— | 93.51 | 235.18 | 413.68 |
Average Common Equity |
— | (17.85) | 139.90 | 395.04 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026